DIVALPROEX SODIUM Drug Patent Profile
✉ Email this page to a colleague
When do Divalproex Sodium patents expire, and when can generic versions of Divalproex Sodium launch?
Divalproex Sodium is a drug marketed by Ajanta Pharma Ltd, Dr Reddys Labs Ltd, Rising, Teva Pharms Usa, Zydus Pharms Usa Inc, Actavis Labs Fl Inc, Anchen Pharms, Apotex, Aurobindo Pharma Ltd, Chartwell Rx, Invatech, Lupin, Mylan, Orbion Pharms, Prinston Inc, Sun Pharm Inds, Teva, Unichem Labs Ltd, Upsher Smith Labs, Amneal Pharms, Amta, Annora Pharma, Cosette, Impax Labs, Lupin Ltd, Reddys, Unichem, and Wockhardt. and is included in thirty-six NDAs.
The generic ingredient in DIVALPROEX SODIUM is divalproex sodium. There are eighteen drug master file entries for this compound. Forty suppliers are listed for this compound. Additional details are available on the divalproex sodium profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Divalproex Sodium
A generic version of DIVALPROEX SODIUM was approved as divalproex sodium by APOTEX on July 29th, 2008.
Summary for DIVALPROEX SODIUM
US Patents: | 0 |
Applicants: | 28 |
NDAs: | 36 |
Finished Product Suppliers / Packagers: | 39 |
Raw Ingredient (Bulk) Api Vendors: | 67 |
Clinical Trials: | 68 |
Patent Applications: | 4,850 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for DIVALPROEX SODIUM |
What excipients (inactive ingredients) are in DIVALPROEX SODIUM? | DIVALPROEX SODIUM excipients list |
DailyMed Link: | DIVALPROEX SODIUM at DailyMed |
Recent Clinical Trials for DIVALPROEX SODIUM
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Emalex Biosciences Inc. | Phase 1 |
Syneos Health | Phase 1 |
Nuventra | Phase 1 |
Pharmacology for DIVALPROEX SODIUM
Drug Class | Anti-epileptic Agent Mood Stabilizer |
Physiological Effect | Decreased Central Nervous System Disorganized Electrical Activity |
Paragraph IV (Patent) Challenges for DIVALPROEX SODIUM
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
DEPAKOTE ER | Extended-release Tablets | divalproex sodium | 500 mg | 021168 | 2005-02-08 | |
DEPAKOTE ER | Extended-release Tablets | divalproex sodium | 250 mg | 021168 | 2004-05-03 |
US Patents and Regulatory Information for DIVALPROEX SODIUM
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Unichem | DIVALPROEX SODIUM | divalproex sodium | TABLET, EXTENDED RELEASE;ORAL | 214643-001 | Feb 25, 2022 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
Teva | DIVALPROEX SODIUM | divalproex sodium | TABLET, DELAYED RELEASE;ORAL | 076941-001 | Jul 29, 2008 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Orbion Pharms | DIVALPROEX SODIUM | divalproex sodium | TABLET, DELAYED RELEASE;ORAL | 078853-001 | Nov 25, 2008 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |